Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights.

Chem Res Toxicol

Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.

Published: April 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mechanism-based inactivation (MBI) refers to the metabolic bioactivation of a xenobiotic by cytochrome P450s to a highly reactive intermediate which subsequently binds to the enzyme and leads to the quasi-irreversible or irreversible inhibition. Xenobiotics, mainly drugs with specific functional units, are the major sources of MBI. Two possible consequences of MBI by medicinal compounds are drug-drug interaction and severe toxicity that are observed and highlighted by clinical experiments. Today almost all of these latent functional groups (e.g., thiophene, furan, alkylamines, etc.) are known, and their features and mechanisms of action, owing to the vast experimental and theoretical studies, are determined. In the past decade, molecular modeling techniques, mostly density functional theory, have revealed the most feasible mechanism that a drug undergoes by P450 enzymes to generate a highly reactive intermediate. In this review, we provide a comprehensive and detailed picture of computational advances toward the elucidation of the activation mechanisms of various known groups with MBI activity. To this aim, we briefly describe the computational concepts to carry out and analyze the mechanistic investigations, and then, we summarize the studies on compounds with known inhibition activity including thiophene, furan, alkylamines, terminal acetylene, etc. This study can be reference literature for both theoretical and experimental (bio)chemists in several different fields including rational drug design, the process of toxicity prevention, and the discovery of novel inhibitors and catalysts.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.chemrestox.0c00483DOI Listing

Publication Analysis

Top Keywords

mechanism-based inactivation
8
p450 enzymes
8
highly reactive
8
reactive intermediate
8
thiophene furan
8
furan alkylamines
8
inactivation cytochrome
4
cytochrome p450
4
enzymes computational
4
computational insights
4

Similar Publications

Hepatocyte apoptosis is a key feature of metabolic dysfunction-associated steatohepatitis (MASH), but the fate of apoptotic hepatocytes in MASH is poorly understood. Here, we explore the hypotheses that clearance of dead hepatocytes by liver macrophages (efferocytosis) is impaired in MASH because of low expression of the efferocytosis receptor T cell immunoglobulin and mucin domain containing 4 (TIM4; gene ) by MASH liver macrophages, which then drives liver fibrosis in MASH. We show that apoptotic hepatocytes accumulate in human and experimental MASH, using mice fed the fructose-palmitate-cholesterol (FPC) diet or the high-fat, choline-deficient amino acid-defined (HF-CDAA) diet.

View Article and Find Full Text PDF

Kinetic and mechanistic investigation toward the characterization of tucatinib inhibition of CYP3A4.

Drug Metab Dispos

August 2025

Pfizer Inc., Pharmacokinetics, Dynamics & Metabolism, Bothell, Washington. Electronic address:

A highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2, tucatinib, has shown remarkable efficacy and safety for treatment of adult patients with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 positive breast cancer, including those with brain metastases. The purpose of this study was to evaluate in vitro the potential to inhibit cytochrome P450 (P450) isoforms for tucatinib. Preliminary in vitro P450 inhibition survey revealed that tucatinib was a weak inhibitor of CYP1A2, CYP2B6, CYP2C19, and CYP2D6 with IC values >20 μM.

View Article and Find Full Text PDF

Introduction: Neuroblastoma, a sympathetic nervous system tumor, is known for its remarkable biological heterogeneity. Unlike other neurogenic malignancies driven by mutations, neuroblastoma carries a significant 'transcriptional burden.' Deregulation of transcription unveils in the course of the tumor's natural history, making the advanced stages of the disease intractable.

View Article and Find Full Text PDF

Nanosomal Irinotecan Targeting Pancreatic Cancer Cell Surface Neuraminidase-1 Sialidase.

Adv Healthc Mater

July 2025

Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo, 001-0021, Japan.

Pancreatic ductal adenocarcinoma (PDAC) is an increasing incidence and is the deadliest cancer. Most pancreatic cancer patients present with nonspecific symptoms at an advanced disease stage that is not amenable to curative surgery. Therapies by immune checkpoint inhibitors have proven difficult in the patients with PDAC.

View Article and Find Full Text PDF

The increasing occurrence of carbapenem resistance (CRAB) has forced clinicians to seek out alternative options with activity against CRAB. CRAB with inactivated PBP7/8 has been shown to result in an increased outer membrane permeability and could serve as a potential new adjuvant target. : Two isogenic clinical isolates of HUMC1 were utilized (WT and HUMC1 ΔPBP7/8).

View Article and Find Full Text PDF